 Connection
Shmuel Yaccoby to Treatment Outcome
This is a "connection" page, showing publications Shmuel Yaccoby has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.069 |
|
|
|
-
Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, Zangari M, Rasche L, Weinhold N, Alapat D, Bellamy W, Ashby C, Mattox S, Epstein J, Yaccoby S, Barlogie B, Hoering A, Bauer M, Walker BA, Davies FE, Morgan GJ. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017 09; 102(9):e364-e367.
Score: 0.017
-
Usmani SZ, Zhang Q, Stratton K, Qu P, Yaccoby S, Hansen E, Steward D, Panozzo S, Petty N, Hoering A, Waheed S, Van Rhee F, Crowley J, Barlogie B. Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma. Leukemia. 2014 Dec; 28(12):2413-5.
Score: 0.014
-
Khan R, Apewokin S, Grazziutti M, Yaccoby S, Epstein J, van Rhee F, Rosenthal A, Waheed S, Usmani S, Atrash S, Kumar S, Hoering A, Crowley J, Shaughnessy JD, Barlogie B. Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma. Leukemia. 2015 May; 29(5):1195-201.
Score: 0.012
-
Barlogie B, van Rhee F, Shaughnessy JD, Epstein J, Yaccoby S, Pineda-Roman M, Hollmig K, Alsayed Y, Hoering A, Szymonifka J, Anaissie E, Petty N, Kumar NS, Srivastava G, Jenkins B, Crowley J, Zeldis JB. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood. 2008 Oct 15; 112(8):3122-5.
Score: 0.009
-
Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD, Epstein J, van Hemert R, Erdem E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangari M, Pineda-Roman M, Mohiuddin A, Yaccoby S, Sawyer J, Angtuaco EJ. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007 Mar 20; 25(9):1121-8.
Score: 0.008
-
Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P, Tricot G. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol. 2005 Oct; 131(1):71-3.
Score: 0.008
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|